COVID-19 has shined a spotlight on the vast potential of digital health, from pandemic response to how clinicians protect and care for patients. Now, Israel-based venture capital firm OTV has closed a $170 million fund aimed at fueling future growth in digital health technologies. In conjunction with the closing, OTV also reported that it has changed its name from Olive Tree Ventures and named Jose Antonio Urrutia Rivas as head of Asia Pacific operations.

PARIS – Corwave SA has obtained $600,000 as part of the Ile-de-France region's stimulus plan, to boost development of its Neptune cardiac support pump. This subsidy is part of the manufacturing recovery plan for the Ile-de-France region, aimed at very small enterprises (VSEs), small and medium-sized enterprises (SMEs) and mid-cap companies. In the midst of the COVID-19 pandemic, the Ile-de-France Region is supporting re-industrialization in a region that brings together 12.1 million inhabitants, or nearly 19% of the French population.

HONG KONG – Singapore-based X-Zell Biotech Pte. Ltd. has emerged as the winner of the Medtech Innovator Asia Pacific 2020 Accelerator program, as determined by a live virtual audience vote. Winning the competition, organized by Medtech Innovator and the Asia Pacific Medical Technology Association (APACMed), earned X-Zell a $150,000 non-dilutive grand prize to advance its business goals and mission.

Following steady expansion of its base among global pharmaceutical companies, Correlia Biosystems Inc. has secured the capital needed to make its nanotechnology-based immunoassay platform commercially available. The company received an infusion of $7 million in series A financing in a round led by Neotribe Ventures with participation by Cota Capital, the Regents of the University of California and others.

Endoscopic ultrasound-guided biopsy startup Limaca Medical Ltd. has raised $1.25 million of a $1.5 million round to advance its next-generation Precision device. The company said it will use the funds to complete first-in-human procedures, conduct postmarket clinical studies and gain regulatory approvals of Precision for gastrointestinal (GI) system and adjacent organ tumors.